Compare PEPG & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEPG | TMCI |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 120.4M |
| IPO Year | 2022 | 2021 |
| Metric | PEPG | TMCI |
|---|---|---|
| Price | $1.83 | $4.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 6 |
| Target Price | ★ $11.17 | $4.77 |
| AVG Volume (30 Days) | 661.1K | ★ 726.2K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $1.01 | $1.17 |
| 52 Week High | $7.80 | $7.78 |
| Indicator | PEPG | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 69.76 |
| Support Level | $1.55 | $2.46 |
| Resistance Level | $5.37 | $4.47 |
| Average True Range (ATR) | 0.10 | 0.39 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 80.87 | 91.60 |
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.